ReViral Ltd.

After pulling back on M&A last year to digest the $43bn acquisition of Seagen in 2023, Pfizer said it is in a position to complete bigger deals this year, but that the company will be strategic ab

The relentless expansion of Pharma’s R&D pipeline was checked somewhat last year, even as the proportion of drugs in active development for cancer reached new heights, and the burgeoning industry in A

The rumors of Pfizer Inc. ’s interest in a mega-purchase of Seagen Inc. became true on 13 March when the companies announced that the big pharma would pay $43bn in cash for the antibody-drug conjug

In a sign of big pharma’s widespread interest in antibody-drug conjugates (ADCs) as a future pillar of cancer treatment, Seagen Inc. is once again said to be in takeover discussions with a large ph